NorthStar Medical Radioisotopes parent NorthStar Medical Technologies has received $11.1 million in matching funds from the U.S. Department of Energy's National Nuclear Security Administration (DOE/NNSA) to support development of the firm's accelerator method for producing molybdenum-99 (Mo-99).
The award is part of a $50 million cooperative agreement between the two organizations in which DOE/NNSA would provide $25 million to match $25 million in funds that had been raised by NorthStar. The NNSA has already fully funded a separate $50 million cooperative agreement that supported NorthStar's neutron activation production method for Mo-99.
